← Leaderboards
Jeffrey J Destefano
University Of Maryland College Pk Campus
$4,935,226
Attributed
$5,218,476
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $361K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,218,476 · 6
By mechanism
R01$4,225,852 · 3
R21$840,624 · 2
R03$152,000 · 1
Top collaborators
- Margaret Adele Scull2 shared
- Xiaoping Zhu2 shared
Others in their field
Top investigators on “Virus Replication”
- Constance Ann Benson · University Of California, San Diego$187,673,896
- Judith S. Currier · University Of California Los Angeles$137,892,773
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Barton F Haynes · Duke University$110,672,613
- Charles M. Rice · Rockefeller University$53,754,576
- Rama Rao Amara · Emory University$53,347,944
Research focus
Virus ReplicationProteinsVirusEvolutionViralAffinityRna-Directed Dna PolymeraseIn VitroNucleic AcidsPharmacotherapyCellsAptamerBaseCell Culture TechniquesPharmaceutical PreparationsDna BiosynthesisMutationImmune ResponseRetroviridaeReverse TranscriptionNucleotidesEnzymesEnvironmentEnzyme Activity
Grant awards (23)
Using new Next Generation Sequencing (NGS) approaches to analyze the fidelity of HIV reverse transcription in Endogenous Reverse Transcription reactions (ERT)$190,620
R21 · FY2024 · AI · contact PI
Using new Next Generation Sequencing (NGS) approaches to analyze the fidelity of HIV reverse transcription in Endogenous Reverse Transcription reactions (ERT)$225,129
R21 · FY2023 · AI · contact PI
Development and Evaluation of Novel Aptamer-based Therapeutics Targeting SARS-CoV-2 in a Physiologically-Relevant Model of Human Airway Epithelium$193,125
R21 · FY2022 · AI · contact PI
Development and Evaluation of Novel Aptamer-based Therapeutics Targeting SARS-CoV-2 in a Physiologically-Relevant Model of Human Airway Epithelium$231,750
R21 · FY2021 · AI · contact PI
Biochemistry of HIV reverse transcriptase fidelity and inhibitor interactions$293,838
R01 · FY2019 · AI · contact PI
Biochemistry of HIV reverse transcriptase fidelity and inhibitor interactions$294,141
R01 · FY2018 · GM · contact PI
Biochemistry of HIV reverse transcriptase fidelity and inhibitor interactions$294,430
R01 · FY2017 · GM · contact PI
Biochemistry of HIV reverse transcriptase fidelity and inhibitor interactions$50,000
R01 · FY2017 · GM · contact PI
Biochemistry of HIV reverse transcriptase fidelity and inhibitor interactions$284,984
R01 · FY2016 · GM · contact PI
Development of an HIV reverse transcriptase aptamer-based detection assay$76,000
R03 · FY2016 · AI · contact PI
Development of an HIV reverse transcriptase aptamer-based detection assay$76,000
R03 · FY2015 · AI · contact PI
Mechanism of recombination by HIV reverse transcriptase$294,030
R01 · FY2011 · GM · contact PI
Mechanism of recombination by HIV reverse transcriptase$297,000
R01 · FY2010 · GM · contact PI
Mechanism of recombination by HIV reverse transcriptase$300,000
R01 · FY2009 · GM · contact PI
Mechanism of recombination by HIV reverse transcriptase$310,500
R01 · FY2008 · GM · contact PI
Mechanism of recombination by HIV reverse transcriptase$246,408
R01 · FY2007 · GM · contact PI
Mechanism of recombination by HIV reverse transcriptase$253,768
R01 · FY2006 · GM · contact PI
Mechanism of recombination by HIV reverse transcriptase$259,875
R01 · FY2005 · GM
Mechanism of recombination by HIV reverse transcriptase$264,355
R01 · FY2004 · GM
MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASE$204,256
R01 · FY2003 · GM
MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASE$198,394
R01 · FY2002 · GM
MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASE$192,700
R01 · FY2001 · GM
MECHANISM OF RECOMBINATION BY HIV REVERSE TRANSCRIPTASE$187,173
R01 · FY2000 · GM